InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,609.12
(
-0.30%
)
US TECH 100
18,829.20
(
-0.97%
)
Dow Jones
41,506.30
(
0.27%
)
Brent Oil
72.33
(
1.32%
)
Bitcoin
57,578.02
(
-2.70%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 136181

Friday, 02/10/2012 3:32:23 PM

Friday, February 10, 2012 3:32:23 PM

Post# of 253125
BIIB discloses unit sales of its MS drugs (as opposed to merely dollar sales) on quarterly CC’s. In the US market—the market of interest for MNTA due to its Copaxone program—4Q11 Avonex unit sales were down YoY (but flat QoQ), while 4Q11 Tysabri unit sales were +10% YoY.

From the 10% YoY growth in unit sales and the 21% YoY growth in dollar sales (#msg-71560226), we know that the average selling price of Tysabri in the US increased by 11% in 4Q11 vs 4Q10.

Source: http://seekingalpha.com/article/328632-biogen-idec-s-ceo-discusses-q4-2011-results-earnings-call-transcript

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up